The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
Open accessAbstract
BACKGROUNDOsimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKIsensitizing and EGFR T790M resistance mutations.A phase 3 trial compared firstline osimertinib with other EGFR-TKIs in patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC).The trial showed longer progressionfree survival with osimertinib than with the comparator EGFR-TKIs (hazard ratio for disease progression or death, 0.46).Data from the final analysis of overall survival have not been reported. METHODSIn this trial, we randomly assigned 556 patients with previously untreated advanced NSCLC with an EGFR mutation (exon 19 deletion or L858R allele) in a 1:1 ratio to receive either osimertinib (80 mg once daily) or one of two other EGFR-TKIs (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily, with patients receiving these drugs combined in a single comparator group).Overall survival was a secondary end point. RESULTSThe median overall survival was 38.6 months (95% confidence interval [CI], 34.5 to 41.8) in the osimertinib group and 31.8 months (95% CI, 26.6 to 36.0) in the comparator group (hazard ratio for death, 0.80; 95.05% CI, 0.64 to 1.00; P = 0.046).At 3 years, 79 of 279 patients (28%) in the osimertinib group and 26 of 277 (9%) in the comparator group were continuing to receive a trial regimen; the median exposure was 20.7 months and 11.5 months, respectively.Adverse events of grade 3 or higher were reported in 42% of the patients in the osimertinib group and in 47% of those in the comparator group. CONCLUSIONSAmong patients with previously untreated advanced NSCLC with an EGFR mutation, those who received osimertinib had longer overall survival than those who received a comparator EGFR-TKI.The safety profile for osimertinib was similar to that of the comparator EGFR-TKIs, despite a longer duration of exposure in the osimertinib group.(Funded by AstraZeneca; FLAURA ClinicalTrials.govnumber, NCT02296125.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The second- and third-generation TKIs have shown significantly longer PFS compared with first-generation TKIs, and the third-generation TKI, osimertinib, has shown superior OS compared with first-generation TKIs.”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [49]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“in the recent FLAURA head-to-head trial, first-line treatment with osimertinib led to superior PFS and OS compared with a first-generation TKI (gefitinib or erlotinib).”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [49]
In the citing paper
“Patients with classical EGFR mutations (L858R or exon 19 deletions (Ex19del)) show marked improvements in clinical outcomes when treated with first-, second- or third-generation tyrosine kinase inhibitors (TKIs)4–6,11.”
From Structure-based classification predicts drug response in EGFR-mutant NSCLC (2021) · cites this paper as [11]
In the citing paper
“In the first line setting, EGFR-tyrosine kinase inhibitors have shown efficacy, particularly with osimertinib. 21 22”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citationOsimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Self-citationRosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Self-citationOsimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Self-citationPlanchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
Self-citationCross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71173-8 · Cited by 1,574
Self-citationMiller, V. A., Hirsh, V., Cadranel, J., Chen, Y.-M., Park, K., Kim, S.-W., Zhou, C., Su, W.-C., Wang, M., Sun, Y., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70087-6 · Cited by 961
Self-citationAzzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5622 · Cited by 915
Reungwetwattana, T., Nakagawa, K., Cho, B. C., Cobo, M., Cho, E. K., Bertolini, A., Bohnet, S., Zhou, C., Lee, K. H., Nogami, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.3118 · Cited by 811
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,003
Treatment of advanced non-small-cell lung cancer
Prabhash, K., Vora, A. D., Limaye, S. A., Sahoo, T. P., Batra, U., Patil, S., Patil, V., Noronha, V., Bhosale, B., Raut, N. V., et al. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_61_21 · Cited by 46
Shen, C., Chiang, C., Shiao, T., Luo, Y., Chao, H., Huang, H.-C., & Chiu, C. (2022) · Scientific Reports · doi:10.1038/s41598-022-17394-7 · Cited by 47
Shi, J., Chen, Y., Peng, C., Kuang, L., Zhang, Z., Li, Y., & Huang, K. (2022) · ONCOLOGIE · doi:10.32604/oncologie.2022.027545 · Cited by 45
Liam, C. K., Ahmad, A. R., Hsia, T., Zhou, J., Kim, D., Soo, R. A., Cheng, Y., Lü, S., Shin, S. W., Yang, J. C., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3318 · Cited by 44
Self-citationRe-evaluating the risk factors for radiation pneumonitis in the era of immunotherapy
Chen, F., Niu, J., Wang, M., Zhu, H., & Guo, Z. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04212-5 · Cited by 45
Chen, F., Chen, N., Yu, Y., & Cui, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00904 · Cited by 45
Kunimasa, K., Oka, T., Hara, S., Yamada, N., Oizumi, S., Miyashita, Y., Kamada, R., Funamoto, T., Kawachi, H., Kawamura, T., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.10.021 · Cited by 44
Self-citationCombining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression
White, M. N., Piotrowska, Z., Stirling, K., Liu, S. V., Banwait, M. K., Cunanan, K. M., Sequist, L. V. D., Wakelee, H. A., Hausrath, D. J., & Neal, J. W. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.01.010 · Cited by 45
Large, T. Y. S. L., Bijlsma, M. F., Hassouni, B. E., Mantini, G., Lagerweij, T., Henneman, A. A., Funel, N., Kok, B., Pham, T. V., Haas, R. D. G.-D., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01892-z · Cited by 44
Wu, Q., Luo, W., Li, W., Wang, T. I., Huang, L., & Xu, F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.598265 · Cited by 44
The storm of NGS in NSCLC diagnostic-therapeutic pathway: How to sun the real clinical practice
Maglio, G. D., Pasello, G., Dono, M., Fiorentino, M., Follador, A., Sciortino, M., Malapelle, U., & Tiseo, M. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103561 · Cited by 46
Self-citationHuang, L., Zhang, S., Han, C., & Ma, J. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.01.014 · Cited by 46
Shimamura, S., Shukuya, T., Asao, T., Hayakawa, D., Kurokawa, K., Xu, S., Miura, K., Mitsuishi, Y., Tajima, K., Shibayama, R., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09421-7 · Cited by 43
Lu, C., Gao, Z., Wu, D., Zheng, J., Hu, C., Huang, D., He, C., Liu, Y., Lin, C., Peng, T., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009165 · Cited by 45
Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing
Christopoulos, P., Kirchner, M., Roeper, J., Saalfeld, F. C., Janning, M., Bozorgmehr, F., Magios, N., Kazdal, D. N., Volckmar, A., Brückner, L. M., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.08.007 · Cited by 43
Qian, G., Guo, J., Vallega, K. A., Hu, C.-J., Chen, Z., Deng, Y., Wang, Q., Fan, S., Ramalingam, S. S., Owonikoko, T. K., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0147 · Cited by 43
Self-citationPredictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value
Chai, X., Yinwang, E., Wang, Z., Wang, Z., Xue, Y., Li, B., Zhou, H., Zhang, W., Wang, S., Zhang, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.692788 · Cited by 43
Yang, X., Liu, M., Ren, Y., Chen, H., Yu, P., Wang, S., Zhang, R., Dai, H., & Wang, C. (2021) · European Radiology · doi:10.1007/s00330-021-08366-y · Cited by 43
Ribeiro, M. F. S. A., Knebel, F. H., Bettoni, F., Saddi, R., Sacardo, K. P., Canedo, F. S. N. A., Alessi, J. V. M., Shimada, A. K., Marin, J. F. G., Camargo, A. A., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00149-4 · Cited by 42
Zhen, J., Wen, L., Lai, M., Zhou, Z., Shan, C., Li, S., Lin, T., Wu, J., Wang, W., Xu, S., et al. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01627-y · Cited by 42
Self-citationKöckinger, M., Wyler, B., Aellig, C., Roberge, D. M., Hone, C. A., & Kappe, C. O. (2020) · Organic Process Research & Development · doi:10.1021/acs.oprd.0c00254 · Cited by 42
Tripathi, S. K., & Biswal, B. K. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.02.005 · Cited by 41
Early-stage ALK-positive lung cancer: a narrative review
Chen, M. F., & Chaft, J. E. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-631 · Cited by 41
Grant, M. J., Aredo, J. V., Starrett, J. H., Stockhammer, P., van Rosenburgh, I. K. V. A., Wurtz, A., Piper-Valillo, A. J., Piotrowska, Z., Falcon, C. J., Yu, H. A., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3497 · Cited by 41
Cheng, Y., Mok, T. S. K., Zhou, X., Lü, S., Zhou, Q. H., Zhou, J., Du, Y., Yu, P., Liu, X., Hu, C., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.02.025 · Cited by 44
Self-citationOsimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data
Lee, C., Milone, M., & Seetharamu, N. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s227032 · Cited by 41
Paz-Ares, L. G., Gondos, Á., Saldaña, D., Thomas, M., Mascaux, C., Bubendorf, L., & Barlési, F. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.01.021 · Cited by 42
Sheffield, B. S., Eaton, K., Émond, B., Lafeuille, M., Hilts, A., Lefèbvre, P., Morrison, L., Stevens, A. L., Ewara, E. M., & Cheema, P. K. (2023) · Current Oncology · doi:10.3390/curroncol30020180 · Cited by 40
Self-citationGarcía‐Campelo, R., Arrieta, O. G., Massutí, B., Rodríguez‐Abreu, D., Granados, A. L. O., Majem, M., Vicente, D., LIANES, P., Bosch‐Barrera, J., Insa, A., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.09.018 · Cited by 41
Chen, J., Facchinetti, F., Brayé, F., Yurchenko, A. A., Bigot, L., Ponce, S., Planchard, D., Gazzah, A., Nikolaev, S. I., Michiels, S., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.01.004 · Cited by 40
Self-citationDuffy, M. J., & Crown, J. P. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010099 · Cited by 40
New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer
Girard, N. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01022-7 · Cited by 40
Popat, S., Ahn, M., Ekman, S., Leighl, N. B., Ramalingam, S. S., Reungwetwattana, T., Siva, S., Tsuboi, M., Wu, Y.-L. L. C., & Yang, J. C. (2023) · Targeted Oncology · doi:10.1007/s11523-022-00941-7 · Cited by 39
Self-citationNeyra, J. A., Legrand, M. M., Tidswell, M., Al-Khafaji, A., Galphin, C. M., Rains, R., Davison, D. L., Tolwani, A., Chen, J.-T., Bender, W., et al. (2026) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(26)00047-0 · Cited by 39
Gu, J., Yao, W., Shi, P., Zhang, G., Owonikoko, T. K., Ramalingam, S. S., & Sun, S. (2020) · Cancer · doi:10.1002/cncr.32996 · Cited by 40
Self-citationTakahashi, S., Noro, R., Seike, M., Zeng, C., Matsumoto, M., Yoshikawa, A., Nakamichi, S., Sugano, T., Hirao, M., Matsuda, K., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084005 · Cited by 39
Li, K., Gao, S., Ma, L., Sun, Y., Peng, Z.-Y., Wu, J., Du, N., Ren, H., Tang, S., & Sun, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.731561 · Cited by 38
Kumar, P. A., Graziano, S. L., Danziger, N. A., Pavlick, D. C., Severson, E. A., Ramkissoon, S. H., Huang, R. S. P., Decker, B. J., & Ross, J. S. (2022) · Cancer Medicine · doi:10.1002/cam4.4971 · Cited by 38
Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
Ji, J., Aredo, J. V., Piper‐Vallillo, A. J., Huppert, L. A., Rotow, J. K., Husain, H., Stewart, S., Cobb, R. G., Wakelee, H. A., Blakely, C. M., et al. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100459 · Cited by 38
Bai, Q., Wang, J., & Zhou, X. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102605 · Cited by 38
Gini, B., Thomas, N. J., & Blakely, C. M. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.03.78 · Cited by 38
Alexander, M., Lin, E. H., & Cheng, H. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00759-3 · Cited by 38
Zeng, Y., Ni, J., Yu, F., Zhou, Y., Zhao, Y., Li, S., Guo, T., Chu, L., Yang, X., Chu, X., et al. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01651-y · Cited by 38
Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment
Filipska, M., & Rosell, R. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12983 · Cited by 38
Chidambaram, S., & Markar, S. R. (2021) · Diseases of the Esophagus · doi:10.1093/dote/doab046 · Cited by 39
Finlay, M. R. V., Barton, P., Bickerton, S., Biśta, M., Colclough, N., Cross, D. A. E., Evans, L., Floc’h, N., Gregson, C. L., Guerot, C. M., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01055 · Cited by 39
Roeper, J., Christopoulos, P., Falk, M., Heukamp, L. C., Tiemann, M., Stenzinger, A., Thomas, M., & Griesinger, F. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-754 · Cited by 38
Application of Circulating Tumor DNA as a Biomarker for Non-Small Cell Lung Cancer
Yang, J., Yan, H., Zhang, Y.-X., Zhang, M., Ji, B., Tian, G., Guo, Y., Tang, M., Li, L., Guo, B., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.725938 · Cited by 37
Brazel, D., Kroening, G., & Nagasaka, M. (2022) · BioDrugs · doi:10.1007/s40259-022-00556-4 · Cited by 37
Wu, T., Yu, B., Xu, Y., Du, Z., Zhang, Z., Wang, Y., Chen, H., Zhang, L., Chen, R., Ma, F., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01400 · Cited by 37
Development of tumor-evolution-targeted anticancer therapeutic nanomedicineEVT
Zhang, L., Yang, J., Huang, J., Yu, Y., Ding, J., Karges, J., & Xiao, H. (2024) · Chem · doi:10.1016/j.chempr.2023.12.019 · Cited by 38
Liang, J., Bi, G., Sui, Q., Zhao, G., Zhang, H., Bian, Y., Chen, Z., Huang, Y., Xi, J., Shi, Y., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113771 · Cited by 38
Laguna, J. C., Tagliamento, M., Lambertini, M., Hiznay, J. M., & Mezquita, L. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432488 · Cited by 40
Peled, N., Tufman, A., Sequist, L. V. D., Pasello, G., Wang, Q., Antonuzzo, L., González-Larriba, J. L., Valdivieso, S. M., Cobo, M., Milella, M., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105807 · Cited by 37
Self-citationJiang, S., Wang, S., Wang, Q., Deng, C., Feng, Y., Ma, F., Ma, J., Liu, X., Hu, C., & Hou, T. (2021) · Cancer Management and Research · doi:10.2147/cmar.s287897 · Cited by 40
Chua, K. P., Teng, Y. H. F., Tan, A. C., Takano, A. M., Alvarez, J. J. S., Nahar, R. R., Rohatgi, N., Lai, G. G. Y., Aung, Z. W., Yeong, J. P.-S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4607 · Cited by 39
Designing small molecules for therapeutic success: A contemporary perspective
Maurer, T. S., Edwards, M. P., Hepworth, D., Verhoest, P. R., & Allerton, C. M. N. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.09.017 · Cited by 39
Minchom, A. R., Viteri, S., Bazhenova, L. A., Gadgeel, S. M., Ou, S. I., Trigo, J. M., Bauml, J. M., Backenroth, D., Bhattacharya, A., Li, T. M. W. Y., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.03.005 · Cited by 37
Michelotti, A., de Scordilli, M., Bertoli, E., Carlo, E. D., Conte, A. D., & Bearz, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126748 · Cited by 37
Takahashi, H., Sakakibara‐Konishi, J., Furuta, M., Shoji, T., Tsuji, K., Morinaga, D., Kikuchi, E., Kikuchi, J., Noguchi, T., Hatanaka, K. C., et al. (2022) · Cancer Science · doi:10.1111/cas.15674 · Cited by 37
Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy
Petrazzuolo, A., Maiuri, M. C., Zitvogel, L., Kroemer, G., & Kepp, O. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2077898 · Cited by 39
Adjuvant Treatments for Surgically Resected Non–Small Cell Lung Cancer Harboring EGFR Mutations
Passaro, A., Mok, T. S. K., Attili, I., Wu, Y.-L. L. C., Tsuboi, M., de Marinis, F., & Peters, S. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.0459 · Cited by 36
Cutting-Edge Therapies for Lung Cancer
La’ah, A. S., & Chiou, S. (2024) · Cells · doi:10.3390/cells13050436 · Cited by 36
Besse, B., Goto, K., Wang, Y., Lee, S., Marmarelis, M. E., Ohe, Y., Bernabé, R., Kim, D., Lee, J.-S., Cousin, S., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.12.029 · Cited by 36
Self-citationAn annual review of the remarkable advances in lung cancer clinical research in 2019
Cheng, B., Xiong, S., Li, C., Liang, H., Zhao, Y., Li, J., Shi, J., Ou, L., Chen, Z., Liang, P., et al. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.03.11 · Cited by 36
Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment
Li, J., & Kwok, H. F. (2020) · Cancers · doi:10.3390/cancers12061587 · Cited by 37
2020 Innovation-Based Optimism for Lung Cancer Outcomes
Schenk, E. L., Patil, T., Pacheco, J. M., & Bunn, P. A. (2020) · The Oncologist · doi:10.1002/onco.13590 · Cited by 37
Kim, E. S., Melosky, B. L., Park, K., Yamamoto, N., & Yang, J. C. (2021) · Future Oncology · doi:10.2217/fon-2021-0195 · Cited by 36
Chen, R., Sun, L., Cao, Y., Chen, H., Zhou, J., Gu, C., Zhang, Y., Wang, S., Hou, W., & Lin, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.629394 · Cited by 35
Hondelink, L. M., Ernst, S. M., Atmodimedjo, P. N., Cohen, D. B., Wolf, J. L., Dingemans, A. C., Dubbink, H. J., & von der Thüsen, J. H. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.12.010 · Cited by 35
Diagnostic and Therapeutic Updates in Leptomeningeal Disease
Roy-O’Reilly, M. A., Lanman, T. A., Ruiz, A. N., Rogawski, D. S., Stocksdale, B. R., & Nagpal, S. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01432-2 · Cited by 37
CDK4/6 inhibitors in lung cancer: current practice and future directions
Lv, S., Yang, J., Lin, J., Huang, X., Zhao, H., Zhao, C., & Yang, L. (2024) · European Respiratory Review · doi:10.1183/16000617.0145-2023 · Cited by 35
Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants
Hayes, T. K., Aquilanti, E., Persky, N. S., Yang, X., Kim, E. E., Brenan, L., Goodale, A. B., Alan, D., Sharpe, T., Shue, R. E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45594-4 · Cited by 36
Puri, S., Leighl, N. B., Ismaila, N., Rous, F. A., Ahluwalia, A., Alluri, K. C., Azar, I. H., Campbell, T., Durm, G. A., Feldman, J., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02822 · Cited by 35
Wu, S.-G., Chiang, C., Liu, C., Wang, C.-C., Su, P., Hsia, T., Shih, J., & Chang, G. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01481 · Cited by 35
Cui, D., Feng, Y., Shi, K., Zhang, H., & Qian, R. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-6331 · Cited by 35
Gu, Y., Lai, S., Dong, Y., Fu, H., Song, L., Chen, T., Duan, Y., & Zhang, Z. (2020) · Advanced Science · doi:10.1002/advs.202002922 · Cited by 35
Provencio, M., Serna‐Blasco, R., Franco, F., Calvo, V., Royuela, A., Auglytė, M., Sánchez-Hernández, A., Campayo, M. D. J., Girón, C. G., Dómine, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.02.031 · Cited by 35
Papini, F., Sundaresan, J., Leonetti, A., Tiseo, M., Rolfo, C. D., Peters, G. J., & Giovannetti, E. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103454 · Cited by 35
Self-citationLiu, S., Jiang, Z., Xiao, P., Li, X., Chen, Y., Tang, H. T., Chai, Y., Liu, Y., Zhu, Z., Xie, Q., et al. (2021) · Cancer Science · doi:10.1111/cas.15177 · Cited by 35
Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer
Yan, D., Earp, H. S., DeRyckere, D., & Graham, D. K. (2021) · Cancers · doi:10.3390/cancers13225639 · Cited by 35
Histologic transformation of epidermal growth factor receptor–mutated lung cancer
Fujimoto, D., Akamatsu, H., Morimoto, T., Wakuda, K., Sato, Y., Kawa, Y., Yokoyama, T., Tamiya, M., Hiraoka, R., Shingu, N., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.02.006 · Cited by 35
High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience
Piper‐Vallillo, A. J., Rotow, J. K., Aredo, J. V., Shaverdashvili, K., Luo, J., Carlisle, J. W., Husain, H., Muzikansky, A., Heist, R. S., Rangachari, D., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100328 · Cited by 35
Self-citationOptimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study
Sun, H., Ren, P., Chen, Y., Lan, L., Yan, Z., Yang, Y., Wang, B., Wang, C., Li, Y., Li, L., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-10637-4 · Cited by 36
Perioperative targeted therapy for oncogene-driven NSCLC
Liu, S. M., Zhang, J.-T., Zeng, K.-H., & Wu, Y.-L. L. C. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.05.007 · Cited by 34
Pezzuto, F., Hofman, V., Bontoux, C., Fortarezza, F., Lunardi, F., Calabrese, F., & Hofman, P. M. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107249 · Cited by 34
Hung, C.-H., Wu, S., Yao, C.-I., Yeh, H.-H., Lin, C., Chu, C., Huang, T.-Y., Shen, M., Lin, C., & Su, W. (2024) · Nature Communications · doi:10.1038/s41467-024-51831-7 · Cited by 35
Li, H., Li, Y., Zheng, X., Chen, F., Zhang, S., Xu, S., Mu, Y., Shen, W., Tong, J., Chen, H., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03220-z · Cited by 38
Penault-Llorca, F. M., & Socinski, M. A. (2024) · The Oncologist · doi:10.1093/oncolo/oyae357 · Cited by 40
Han, R., Hao, S., Lu, C., Zhang, C., Lin, C., Li, L., Wang, Y., Hu, C., & He, Y. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12682 · Cited by 34
Cheema, P. K., Gomes, M. M., Banerji, S. O., Joubert, P., Leighl, N. B., Melosky, B. L., Sheffield, B. S., Stockley, T. L., & Ionescu, D. N. (2020) · Current Oncology · doi:10.3747/co.27.7297 · Cited by 34
Self-citationXu, K., Liang, J., Zhang, T., Zhou, Z., Chen, D., Feng, Q., Xiao, Z., Hui, Z., Lü, J.-M., Wang, X., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13816 · Cited by 34
Li, L., Li, Z., Lu, C., Li, J., Zhang, K., Lin, C., Tang, X., Liu, Z., Zhang, Y., Han, R., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03111-7 · Cited by 34
Sentana‐Lledo, D., Academia, E. C., Viray, H., Rangachari, D., Kobayashi, S. S., VanderLaan, P. A., & Costa, D. B. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-98 · Cited by 34
Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
Mambetsariev, I., Arvanitis, L. D., Fricke, J., Pharaon, R. R., Baroz, A. R., Afkhami, M., Koczywas, M., Massarelli, E., & Salgia, R. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051429 · Cited by 33
Remón, J., Besse, B., Aix, S. P., Callejo, A., Al-Rabi, K. H., Bernabé, R., Greillier, L., Majem, M., Reguart, N., Monnet, I., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01521 · Cited by 33
Gray, J. E., Markovets, A. A., Reungwetwattana, T., Majem, M., Nogami, N., Peled, N., Lee, J. S., Cho, B. C., Chewaskulyong, B., John, T., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.07.008 · Cited by 33
Self-citationThe Risk and Reversibility of Osimertinib-Related Cardiotoxicity in a Real-World Population
Bak, M., Park, H., Lee, S., Lee, N., Ahn, M., Ahn, J. S., Jung, H. A., Park, S., Cho, J., Kim, J., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.10.003 · Cited by 33
Multimodal scanning of genetic variants with base and prime editing
Belli, O., Karava, K., Farouni, R., & Platt, R. J. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02439-1 · Cited by 34
Lee, S., Menis, J., Kim, T. M., Kim, H. R., Zhou, C., Kurniawati, S., Prabhash, K., Hayashi, H., Lee, D. D.-W., Imasa, M. S. B., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103996 · Cited by 33
Self-citation
Metadata
- Authors
- Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., Shah, R., Cobo, M., Lee, K. H., Cheema, P., Tiseo, M., John, T., Lin, M.-C., Imamura, F., Kurata, T., Todd, A., Hodge, R., Saggese, M., Rukazenkov, Y., & Soria, J.-C.
- Affiliations
- Université Paris-Sud (FR)
- From Winship Cancer Institute, Emory University School of Medicine, Atlanta (S.S.R.); the Respiratory Oncology Unit, Department of Respiratory Medicine, University Hospital KU Leuven, Leuven, Belgium (J.V.); the Thoracic Unit, Department of Medical Oncology, Institut Gustave Roussy, Villejuif (D.P., J.-C.S.), and University Paris Sud, Orsay (J.-C.S.) — both in France; the Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul...
- ORCID
- Ramalingam, Suresh S.
- Vansteenkiste, Johan
- Planchard, David
- Cho, Byoung Chul
- Gray, Jhanelle E.
- Ohe, Yuichiro
- Zhou, Caicun
- Reungwetwattana, Thanyanan
- Cheng, Ying
- Shah, Riyaz
- Cobo, Manuel
- Lee, Ki Hyeong
- Cheema, Parneet
- Tiseo, Marcello
- John, Thomas
- Lin, Meng-Chih
- Imamura, Fumio
- Kurata, Takayasu
- Todd, Alexander
- Hodge, Rachel
- Soria, Jean-Charles
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-01-02
- Volume
- 382
- Issue
- 1
- Pages
- 41-50
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2990041408
- Cited by
- 2,914
- References
- 27
- Citations by year
- 2026: 354 · 2025: 462 · 2024: 487 · 2023: 411 · 2022: 480 · 2021: 434 · 2020: 284
- FWCI
- 222.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Lirias (submittedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- AstraZeneca (N/A)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- osimertinib, EGFR-mutant non-small cell lung cancer, EGFR tyrosine kinase inhibitors, gefitinib, erlotinib, first-line therapy, overall survival, exon 19 deletion, L858R mutation, T790M resistance, progression-free survival, adverse events, treatment duration
- MeSH terms
- Erlotinib Hydrochloride, Gefitinib, Acrylamides, Aged, Aniline Compounds, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Mutation, Pyrimidines, Proportional Hazards Models, Protein Kinase Inhibitors, Kaplan-Meier Estimate, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
